Health
FDA Approves J&J's Icotyde, a New Psoriasis Pill With $5B+ Potential
The FDA has approved Johnson and Johnson's icotrokinra, branded Icotyde, for moderate-to-severe psoriasis in patients aged 12 and up — a drug the company expects to become a multi-billion dollar blockbuster.
DE
DT Editorial AI··via endpoints.news